1 Stock to Buy in Q4 if You Haven't Already

NYSE: CVS | CVS Health Corporation  News, Ratings, and Charts

CVS – Health service provider CVS Health (CVS) is aiming for an $8 billion acquisition of Signify Health (SGFY). The company’s strength is reflected in its latest quarterly financials. Hence, the stock might be a solid buy in the fourth quarter. Let’s find out….

Health services provider CVS Health Corporation (CVS - Get Rating) operates in three segments, Health Care Benefits; Pharmacy Services; and Retail/LTC.

On September 5, 2022, CVS announced its agreement to acquire Signify Health, Inc. (SGFY) for $30.50 per share in cash, amounting to a total transaction value of approximately $8 billion. If this acquisition carries through, it is expected to strengthen the company’s ability to provide new product offerings in a multi-payor approach.

On November 2, 2022, Karen S. Lynch, CVS’ President and CEO, said, “We continue to execute on our strategy with a focus on expanding capabilities in healthcare delivery, and the announced acquisition of Signify Health will further strengthen our engagement with consumers.”

In addition, CVS has paid dividends for 14 consecutive years. Its dividend payouts have increased at a 3.2% CAGR over the past three years. Its current dividend yield is 2.33%, and its four-year average yield is 2.79%.

Over the past month, CVS has lost marginally to close the last trading session at $94.62. It has lost 8.3% year-to-date. However, the stock has gained 4.4% over the past year. Moreover, Wall Street analysts expect the stock to hit $122.00 in the near term, indicating a potential upside of 28.9%.

Here is what could shape CVS’ performance in the near term:

Solid Financials

CVS’ total revenues increased 10% year-over-year to $81.16 billion for the third quarter ended on September 30, 2022. Its adjusted operating income came in at $4.23 billion, up 3.9% year-over-year. Moreover, its adjusted EPS came in at $2.09, up 6.1% year-over-year.

Attractive Valuation

CVS’ forward EV/Sales of 0.59x is 85% lower than the industry average of 3.91x, while its forward EV/EBITDA of 9.15x is 31.1% lower than the industry average of 13.28x. Also, its forward Price/Sales of 0.40x compared with the industry average of 4.39x, and its forward Price/Book of 1.56x is 41% lower than the industry average of 2.64x. 

Strong Profitability

CVS’ trailing-12-month EBITDA margin of 6.14% is 86.4% higher than the industry average of 3.29%. Its trailing-12-month net income margin of 2.66% is higher than the negative industrial average of 3.14%.

Furthermore, its trailing-12-month ROCE, ROTC, and ROTA of 11.00%, 5.96%, and 3.55% compare with the industry averages of negative 38.97%, 21.70%, and 29.73%, respectively.

POWR Ratings Reflect Promising Outlook

CVS has an overall A rating, which equates to a Strong Buy in our proprietary POWR Ratings system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.

Our proprietary rating system also evaluates each stock based on eight distinct categories. The stock has a B grade for Growth, consistent with its solid financials in the latest reported quarter. It has a B grade for Stability, in sync with its beta of 0.71.

In the four-stock Medical – Drug Stores industry, CVS is ranked first.

Click here for the additional POWR Ratings for CVS (Value, Momentum, Sentiment, Quality).

View all the top stocks in the Medical – Drug Stores industry here.

Bottom Line

CVS witnessed solid year-over-year growth in its third-quarter financials. Furthermore, analysts expect its revenue to grow 6.9% year-over-year to $312.36 billion in 2022. Given the stock’s attractive valuations and robust profitability, CVS might be a solid addition to your portfolio ahead of the fourth quarter.

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


CVS shares were trading at $98.56 per share on Wednesday morning, up $3.94 (+4.16%). Year-to-date, CVS has declined -2.30%, versus a -18.56% rise in the benchmark S&P 500 index during the same period.


About the Author: Riddhima Chakraborty


Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
CVSGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Stock Market Update: It’s Complicated!

The S&P 500 (SPY) may have bounced 17% from recent lows, but the outlook for stocks from here is...in a word...COMPLICATED. Read on to get Steve Reitmeister full market outlook and trading plan for this complicated market environment.

Becoming More Bullish on Stocks, But...

Stocks are on a roll with the S&P 500 (SPY) up more than 10% from the recent lows. Before you start getting too giddy, you should read this updated market outlook and trading plan Steve Reitmeister.

Stock Market Held Hostage

Uncertainty is the term most often applied to this stock market. Uncertainty over tariffs. Uncertainty of whether the S&P 500 (SPY) will fall into bear territory. Uncertainty over what happens next. Steve Reitmeister dives into the uncertainty to make sense of the market in this week’s commentary...

Stock Market Standing on the 50 Yard Line

Steve Reitmeister contemplates where the stock market stands now and what happens next in trying to stay on the right side of the market action. One path points to bear and one to new highs for the S&P 500 (SPY). Which will it be?

Bear or Bull Market?

The S&P 500 is on the brink of bear market territory...but that outcome is not a given at this time. Steve Reitmeister shares insights gleaned from his 45 years of investing to shine a light on current conditions along with his top picks...

Read More Stories

More CVS Health Corporation (CVS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CVS News